恶性肿瘤相关静脉血栓栓塞症的研究进展

静脉血栓栓塞症（VTE）是恶性肿瘤的常见并发症之一，发生率为4％～20％，也是导致肿瘤患者死亡的主要原因之一。住院和接受积极治疗的肿瘤患者是VTE的高发人群。VTE将增加肿瘤患者的致残率和致死率，影响抗肿瘤的疗效，加重医疗资源及患者的负担。国际上采用风险预测模型可以有效评估VTE的风险因素，以便有针对性地实施预防性抗凝治疗策略。近年来越来越多的临床研究显示，在肿瘤患者中积极防治VET有较多的益处。

Prevention and treatment progress of tumor-associated venous thromboembolism

Venous thromboembolism（VTE） is a common complication and one of the most leading causes of death in patients with cancer. In addition to surgery and prolonged hospital stays, chemotherapy is increasingly recognized as a risk factor for VTE in pa- tients with cancer. VTE will increase the morbidity and mortality in cancer patients, influence the anti-tumor effects and aggravate the medical resources and patients＇ economic burdens. Recently, risk prediction models are used for effective assessment of the risk factors for VTE. More and more clinical trials show benefits of prophylaxis and treatment for cancer patients.